Reed Jobs Focuses on Biotech Investments as AI Reshapes Drug Development

Reed Jobs, founder of venture firm Yosemite, said the company has grown to a team of 17 since launching roughly three years ago. In a recent interview, he noted that the pace of progress has exceeded his initial expectations, driven by two major shifts in the biotech industry. The first is a cluster of blockbuster drugs losing patent protection around the same time, which opens up opportunities for generic and biosimilar manufacturers. The second is the deepening role of artificial intelligence in drug discovery and development, which Jobs described as a major component of Yosemite’s current operations.

The patent cliff creates a clear window for investors and businesses that can move quickly to capture market share. Companies that specialize in developing versions of off-patent drugs or that focus on novel formulations stand to benefit. Additionally, AI tools are increasingly being used to analyze biological data, speed up clinical trials, and identify new drug targets, which can reduce costs and shorten time to market.

For individual investors, this environment suggests that biotech-focused exchange-traded funds and small-cap pharmaceutical companies with strong AI partnerships may be worth watching. Venture capitalists and angel investors might look for startups that combine AI and drug repurposing strategies. Real estate investors could also find opportunities in laboratory and research facility space, especially in biotech hubs like Boston, San Francisco, and San Diego.

Side hustles and freelance professionals with skills in data science, bioinformatics, or AI model training may find growing demand from biotech firms looking to build in-house capabilities. The convergence of patent expirations and AI adoption is likely to accelerate deal-making and job creation in the sector over the next few years.